Vivos Therapeutics, Inc. has announced the publication of positive results from a multicenter clinical trial on its Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in ...
LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...
Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model Vivos’ DNA appliance now ...
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, which is used to treat moderate to severe obstructive sleep apnea (OSA) and ...
Vivos announces immediate expansion of its new alliance model into two additional Colorado locations as initial reports show sleep apnea patients prefer Vivos CARE treatment for OSA nearly 2 to 1 over ...
LITTLETON, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results